ASCO 2026 Highlights – Part 1: Landmark Advances in Targeted Therapy

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(397)

LCC Advances in ALK+ Cancer in Cantonese

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The...

14 Aug 46min

Treating Advanced Thymic Cancers

Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined...

4 Aug 59min

FDA Approval: Zidesamtinib and ROS1 NSCLC

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephe...

28 Jul 24min

Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore ...

21 Jul 47min

IASLC - Your First Faculty Job

Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition ...

7 Jul 41min

Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered

In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped ...

23 Jun 45min

Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights -...

12 Jun 39min

ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy adva...

9 Jun 40min